149 related articles for article (PubMed ID: 30956977)
21. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007.
Couchman L; Morgan PE; Spencer EP; Flanagan RJ
Ther Drug Monit; 2010 Aug; 32(4):438-47. PubMed ID: 20463634
[TBL] [Abstract][Full Text] [Related]
22. Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Clozapine.
Geers LM; Cohen D; Wehkamp LM; van Hateren K; Koster RA; Fedorenko OY; Semke AV; Bokhan N; Ivanova SA; Kosterink JGW; Loonen AJM; Touw DJ
J Clin Psychiatry; 2017; 78(9):e1211-e1218. PubMed ID: 29068609
[TBL] [Abstract][Full Text] [Related]
23. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia.
Rajkumar AP; Poonkuzhali B; Kuruvilla A; Jacob M; Jacob KS
Int Clin Psychopharmacol; 2013 Jan; 28(1):50-6. PubMed ID: 23104241
[TBL] [Abstract][Full Text] [Related]
24. Prediction of brain clozapine and norclozapine concentrations in humans from a scaled pharmacokinetic model for rat brain and plasma pharmacokinetics.
Li CH; Stratford RE; Velez de Mendizabal N; Cremers TI; Pollock BG; Mulsant BH; Remington G; Bies RR
J Transl Med; 2014 Aug; 12():203. PubMed ID: 25142323
[TBL] [Abstract][Full Text] [Related]
25. Field-amplified sample stacking in capillary electrophoresis for the determination of clozapine, clozapine N-oxide, and desmethylclozapine in schizophrenics' plasma.
Ho YH; Ko WK; Kou HS; Wu HL; Wu SM
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Sep; 809(1):111-6. PubMed ID: 15282100
[TBL] [Abstract][Full Text] [Related]
26. Clozapine: more than 900 mg/day may be needed.
Maccall C; Billcliff N; Igbrude W; Natynczuk S; Spencer EP; Flanagan RJ
J Psychopharmacol; 2009 Mar; 23(2):206-10. PubMed ID: 18515467
[TBL] [Abstract][Full Text] [Related]
27. Variability of the in vivo metabolism of clozapine.
Raedler TJ; Hinkelmann K; Wiedemann K
Clin Neuropharmacol; 2008; 31(6):347-52. PubMed ID: 19050412
[TBL] [Abstract][Full Text] [Related]
28. Features and toxicokinetics of clozapine in overdose.
Reith D; Monteleone JP; Whyte IM; Ebelling W; Holford NH; Carter GL
Ther Drug Monit; 1998 Feb; 20(1):92-7. PubMed ID: 9485562
[TBL] [Abstract][Full Text] [Related]
29. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking.
Hasegawa M; Gutierrez-Esteinou R; Way L; Meltzer HY
J Clin Psychopharmacol; 1993 Dec; 13(6):383-90. PubMed ID: 8120151
[TBL] [Abstract][Full Text] [Related]
30. The Drug-Drug Effects of Rhein on the Pharmacokinetics and Pharmacodynamics of Clozapine in Rat Brain Extracellular Fluid by In Vivo Microdialysis.
Hou ML; Lin CH; Lin LC; Tsai TH
J Pharmacol Exp Ther; 2015 Oct; 355(1):125-34. PubMed ID: 26220937
[TBL] [Abstract][Full Text] [Related]
31. Population Pharmacokinetics of Clozapine: A Systematic Review.
Albitar O; Harun SN; Zainal H; Ibrahim B; Sheikh Ghadzi SM
Biomed Res Int; 2020; 2020():9872936. PubMed ID: 31998804
[TBL] [Abstract][Full Text] [Related]
32. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients.
Perry PJ; Miller DD; Arndt SV; Cadoret RJ
Am J Psychiatry; 1991 Feb; 148(2):231-5. PubMed ID: 1670979
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic drug monitoring of clozapine and norclozapine in human serum using ultra-performance liquid chromatography- tandem mass spectrometry.
Ming DS; Heathcote J
J Anal Toxicol; 2009 May; 33(4):198-203. PubMed ID: 19470221
[TBL] [Abstract][Full Text] [Related]
34. Retrospective evaluation of therapeutic drug monitoring of clozapine and norclozapine in Belgium using a multidrug UHPLC-MS/MS method.
Patteet L; Maudens KE; Vermeulen Z; Dockx G; De Doncker M; Morrens M; Sabbe B; Neels H
Clin Biochem; 2014 Dec; 47(18):336-9. PubMed ID: 25289972
[TBL] [Abstract][Full Text] [Related]
35. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients.
Rostami-Hodjegan A; Amin AM; Spencer EP; Lennard MS; Tucker GT; Flanagan RJ
J Clin Psychopharmacol; 2004 Feb; 24(1):70-8. PubMed ID: 14709950
[TBL] [Abstract][Full Text] [Related]
36. Clinical pharmacokinetics of clozapine in chronic schizophrenic patients.
Cheng YF; Lundberg T; Bondesson U; Lindström L; Gabrielsson J
Eur J Clin Pharmacol; 1988; 34(5):445-9. PubMed ID: 3203703
[TBL] [Abstract][Full Text] [Related]
37. Branded versus generic clozapine: bioavailability comparison and interchangeability issues.
Lam YW; Ereshefsky L; Toney GB; Gonzales C
J Clin Psychiatry; 2001; 62 Suppl 5():18-22; discussion 23-4. PubMed ID: 11305844
[TBL] [Abstract][Full Text] [Related]
38. Effect of hypertriglyceridemia on the pharmacokinetics and blood-brain barrier penetration of clozapine and norclozapine following administration to rats.
Gershkovich P; Sivak O; Sharma A; Barr AM; Procyshyn R; Wasan KM
Eur Neuropsychopharmacol; 2010 Aug; 20(8):545-52. PubMed ID: 20163937
[TBL] [Abstract][Full Text] [Related]
39. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.
Jaquenoud Sirot E; Knezevic B; Morena GP; Harenberg S; Oneda B; Crettol S; Ansermot N; Baumann P; Eap CB
J Clin Psychopharmacol; 2009 Aug; 29(4):319-26. PubMed ID: 19593168
[TBL] [Abstract][Full Text] [Related]
40. Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter- and intraindividual variations of clozapine clearance.
Dailly E; Urien S; Chanut E; Claudel B; Guerra N; Femandez C; Jolliet P; Bourin M
Prog Neuropsychopharmacol Biol Psychiatry; 2002 May; 26(4):699-703. PubMed ID: 12188102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
